Inhibrx (INBX) Insider Trading & Ownership $14.04 -0.25 (-1.75%) (As of 11/20/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Inhibrx (NASDAQ:INBX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage22.20%Number OfInsiders Buying(Last 12 Months)3Amount OfInsider Buying(Last 12 Months)$2.63 MNumber OfInsiders Selling(Last 12 Months)1Amount OfInsider Selling(Last 12 Months)$10.29 M Get INBX Insider Trade Alerts Want to know when executives and insiders are buying or selling Inhibrx stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address INBX Insider Buying and Selling by Quarter Ad Wide Moat ResearchTrump said you could learn something from this manEarly Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement. Here’s everything you need to know. Inhibrx Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails9/16/2024Mark LappeCEOBuy13,037$17.13$223,323.81 9/12/2024Mark LappeCEOBuy26,963$15.05$405,793.15 9/10/2024Kristiina Md VuoriDirectorBuy179$15.00$2,685.00 9/9/2024Mark LappeCEOBuy9,500$15.21$144,495.00 9/6/2024Mark LappeCEOBuy26,000$15.29$397,540.00 9/3/2024Mark LappeCEOBuy20,000$15.81$316,200.00 8/29/2024Mark LappeCEOBuy10,000$14.03$140,300.00 6/5/2024Jon Faiz KayyemDirectorBuy57,549$17.32$996,748.68 5/28/2024Brendan P EckelmanInsiderSell300,000$34.30$10,290,000.00 (Data available from 1/1/2013 forward) INBX Insider Trading Activity - Frequently Asked Questions Who is on Inhibrx's Insider Roster? The list of insiders at Inhibrx includes Brendan P Eckelman, Global Investors Lp Viking, Jon Faiz Kayyem, Kristiina Md Vuori, and Mark Lappe. Learn more on insiders at INBX. What percentage of Inhibrx stock is owned by insiders? 22.20% of Inhibrx stock is owned by insiders. Learn more on INBX's insider holdings. Which Inhibrx insiders have been buying company stock? The following insiders have purchased INBX shares in the last 24 months: Global Investors Lp Viking ($9,899,982.45), Jon Faiz Kayyem ($996,748.68), Kristiina Md Vuori ($2,685.00), and Mark Lappe ($1,627,651.96). How much insider buying is happening at Inhibrx? Insiders have purchased a total of 674,855 INBX shares in the last 24 months for a total of $12,527,068.09 bought. Which Inhibrx insiders have been selling company stock? The following insiders have sold INBX shares in the last 24 months: Brendan P Eckelman ($12,871,701.65), Jon Faiz Kayyem ($780,615.00), and Mark Lappe ($1,213,984.40). How much insider selling is happening at Inhibrx? Insiders have sold a total of 477,810 Inhibrx shares in the last 24 months for a total of $14,866,301.05 sold. Inhibrx Key ExecutivesMr. Mark Paul Lappe (Age 57)Founder, Chairman, President & CEO Compensation: $1.1MDr. Brendan P. Eckelman Ph.D. (Age 45)Founder & Chief Scientific Officer Compensation: $769.25kMs. Kelly Devine Deck B.S. (Age 44)CPA, M.S., Executive VP & CFO Compensation: $636.87kMr. Quinn L. DeverauxFounderDr. Ashraf Amanullah (Age 56)Executive VP & Chief Technical Operations Officer Ms. Leah Pollema J.D.VP, Corporate Secretary & General CounselDr. Charbel Helaihel Pharm.D.Vice President of Marketing & Commercial PlanningMr. Jeffrey J. JensenExecutive VP & Chief Clinical Operations OfficerMr. David Matly M.B.A.Executive VP and Chief Commercial & Business Development OfficerDr. Carlos Bais Ph.D.Executive Vice President of Translational Sciences More Insider Trading Tools from MarketBeat Related Companies Pieris Pharmaceuticals Insider Selling Rapport Therapeutics Insider Selling Tyra Biosciences Insider Selling Evolus Insider Selling Relay Therapeutics Insider Selling Prothena Insider Selling Pliant Therapeutics Insider Selling Cronos Group Insider Selling Replimune Group Insider Selling Erasca Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking On This page (NASDAQ:INBX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibrx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibrx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
